# A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

> **NCT00742560** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 101 (actual)

## Conditions studied

- Hematologic Cancer

## Interventions

- **BIOLOGICAL:** elotuzumab
- **DRUG:** lenalidomide
- **DRUG:** dexamethasone oral
- **DRUG:** dexamethasone injection

## Key facts

- **NCT ID:** NCT00742560
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2018-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742560, "A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00742560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*